基层慢阻肺数字疗法实施效果评价

注册号:

Registration number:

ChiCTR2500114470 

最近更新日期:

Date of Last Refreshed on:

2025-12-12 11:21:21 

注册时间:

Date of Registration:

2025-12-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基层慢阻肺数字疗法实施效果评价

Public title:

Evaluation of the implementation effect of digital therapy for chronic obstructive pulmonary disease at the grassroots level

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基层慢阻肺数字疗法实施效果评价

Scientific title:

Evaluation of the implementation effect of digital therapy for chronic obstructive pulmonary disease at the grassroots level

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐佳怡 

研究负责人:

杜汋 

Applicant:

Xu Jiayi 

Study leader:

Du Yue 

申请注册联系人电话:

Applicant telephone:

+86 136 6479 1614

研究负责人电话:

Study leader's
telephone:

+86 189 2001 5698

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xuxiaojia0611@163.com

研究负责人电子邮件:

Study leader's E-mail:

duyue@tmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市和平区气象台路22号

研究负责人通讯地址:

天津市河北区中山路一号

Applicant address:

No. 22, Meteorological Road, Heping District, Tianjin

Study leader's address:

No. 1, Zhongshan Road, Hebei District, Tianjin

申请注册联系人邮政编码:

Applicant postcode:

300041

研究负责人邮政编码:

Study leader's postcode:

300041

申请人所在单位:

天津医科大学公共卫生学院

Applicant's institution:

School of Public Health,Tianjin Medical University

研究负责人所在单位:

天津市第四中心医院

Affiliation of the Leader:

Tianjin Fourth Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SZXLL-2025-087

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津市第四中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of Tianjin Fourth Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-12-09 00:00:00

伦理委员会联系人:

方涛

Contact Name of the ethic committee:

Fang Tao

伦理委员会联系地址:

天津市河北区中山路一号

Contact Address of the ethic committee:

No. 1, Zhongshan Road, Hebei District, Tianjin

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 187 2206 7102

伦理委员会联系人邮箱:

Contact email of the ethic committee:

tjzdxk@163.com

研究实施负责(组长)单位:

天津市第四中心医院

Primary sponsor:

Tianjin Fourth Central Hospital

研究实施负责(组长)单位地址:

天津市河北区中山路一号

Primary sponsor's address:

No. 1, Zhongshan Road, Hebei District, Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

和平区

Country:

China

Province:

Tianjin

City:

Heping District

单位(医院):

天津市第四中心医院

具体地址:

天津市河北区中山路一号

Institution
hospital:

Tianjin Fourth Central Hospital

Address:

No. 1, Zhongshan Road, Hebei District, Tianjin

经费或物资来源:

天津市哲学社会科学规划年度项目,项目编码:TJSR24-001

Source(s) of funding:

Tianjin Philosophy and Social Sciences Planning Annual Project, Project Code: TJSR24-001

研究疾病:

慢性阻塞性肺疾病  

Target disease:

Chronic Obstructive Pulmonary Disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价并分析基于数字疗法的慢阻肺患者管理模式与传统管理模式在社区慢阻肺患者管理中的应用效果与差异。  

Objectives of Study:

Evaluate and analyze the application effects and differences of the chronic obstructive pulmonary disease (COPD) patient management model based on digital therapy and the traditional management model in the management of COPD patients in the community.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.视力、听力、认知功能障碍无法正常沟通者; 2.既往精神病史不能配合者; 3.合并有严重器质性心脏病、恶性肿瘤、肝肾功能障碍等疾病; 4.无法使用智能用药传感器,机体极度虚弱者等。

Exclusion criteria:

1. Individuals with visual, auditory, or cognitive impairments preventing normal communication; 2. Those with a history of psychiatric disorders rendering them non-cooperative; 3. Patients with concomitant severe organic heart disease, malignant tumours, hepatic or renal dysfunction, or similar conditions; 4. Individuals unable to utilise smart medication sensors, or those in a state of extreme physical debility.

研究实施时间:

Study execute time:

From 2025-12-25 00:00:00 To 2026-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-25 00:00:00 To 2026-03-30 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

74

Group:

Control group

Sample size:

干预措施:

社区卫生服务中心的常规管理

干预措施代码:

Intervention:

The routine management of the community health service center

Intervention code:

组别:

干预组

样本量:

74

Group:

Intervention group

Sample size:

干预措施:

在常规管理基础上应用数字疗法进行干预

干预措施代码:

Intervention:

Intervene by applying digital therapy on the basis of conventional management

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津市 

市(区县):

西青区 

Country:

China

Province:

Tianjin

City:

Xiqing District

单位(医院):

天津市西青区中北镇社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Community Health Service Center of Zhongbei Town, Xiqing District, Tianjin

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

天津市 

市(区县):

滨海新区 

Country:

China

Province:

Tianjin

City:

Binhai New Area

单位(医院):

天津市滨海新区胡家园街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Hujiayuan Street Community Health Service Center, Binhai New Area, Tianjin

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

天津市 

市(区县):

河东区 

Country:

China

Province:

Tianjin

City:

Hedong District

单位(医院):

天津市河东区向阳楼街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Xiangyanglou Street Community Health Service Center, Hedong District, Tianjin

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

天津市 

市(区县):

东丽区 

Country:

China

Province:

Tianjin

City:

Dongli District

单位(医院):

天津市东丽区丰年村街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Fengnian Village Street Community Health Service Center, Dongli District, Tianjin

Level of the institution:

Community Health Service Center

测量指标:

Outcomes:

指标中文名:

慢阻肺评估测试评分

指标类型:

主要指标

Outcome:

COPD Assessment Test score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良版英国医学研究委员会呼吸困难问卷评分

指标类型:

主要指标

Outcome:

Modified British medical research council score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺功能检查结果

指标类型:

主要指标

Outcome:

Pulmonary function test results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

干预期内慢阻肺病急性加重发生率

指标类型:

主要指标

Outcome:

The incidence rate of acute exacerbation of chronic obstructive pulmonary disease during the intervention period

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Morisky用药依从性量表评分

指标类型:

次要指标

Outcome:

Eight-item Morisky Medication Adherence Scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

圣乔治呼吸问卷评分

指标类型:

次要指标

Outcome:

St. George's Respiratory Questionnaire score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

五水平五维健康量表评分

指标类型:

次要指标

Outcome:

Five-level Five-dimensional Health Scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 35 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

简单随机分组,研究人员根据Excel中的Rand函数生成0~1的随机数字,再将随机数字按从小到大进行排序,序号为1~74划分为对照组(n=74),序号为75~148划分为干预组(n=74)。

Randomization Procedure (please state who generates the random number sequence and by what method):

Simple random grouping was conducted. Researchers generated random numbers ranging from 0 to 1 using the Rand function in Excel, and then sorted these numbers in ascending order. The subjects with sequence numbers 1 to 74 were assigned to the control group (n = 74), while those with sequence numbers 75 to 148 were assigned to the intervention group (n = 74).

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签

Blinding:

Open label

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理包括病例记录表和电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management include CFR and EDC.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-12 11:21:08